Does Tamsulosin Facilitate Semi-rigid Ureteroscopic

Sponsor
Assiut University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04602403
Collaborator
(none)
100
1
2
12
8.3

Study Details

Study Description

Brief Summary

Ureteric calculi are one of the most common reasons for frequent Urolithiasis. The estimated prevalence is 8-13% of all calculi.

Medical expulsive therapy (MET) is recommended by the European Association of Urology (EAU) (2013) for 5-10 mm ureteric stones to facilitate stone passage. For MET, alpha blockers, mainly tamsulosin, have shown efficacy in several randomized controlled trials. The underlying pathophysiology of this therapy is supported by the presence and distribution of adrenoreceptors in the ureter. Blocking the action of alpha-1 receptors by pharmacological agents (alpha blockers), such as alfuzosin, terazosin, doxazosin, and, most typically, tamsulosin, results in the relaxation of the ureteric smooth muscle.

Ureteroscopy (URS) is the most commonly performed procedure for the treatment of ureteral calculi, with a high (>90%) stone-free rate after a single treatment. Advancing a rigid ureteroscope into a non-dilated ureter may be difficult and cause complications. Ureteric dilatation may provide access to stones, but not in all cases, and ureteral mucosal injury up to perforation might occur.

Condition or Disease Intervention/Treatment Phase
  • Procedure: rigid ureteroscopy
N/A

Detailed Description

Based on the role of alpha blockers, mainly tamsulosin, in MET of ureteric calculus, the investigator will attempt to extend the use of alpha blockers prior to URS for procedural ease. the investigator will conduct a prospective, randomized double-blind study to evaluate whether alpha blockers facilitate the negotiation of the ureteroscope if administered preoperatively.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Other
Official Title:
Does Preoperative Tamsulosin Facilitate Semi-rigid Ureteroscopic Management of Lower Ureteric Calculi Prospective, Randomized Double Blind Study
Actual Study Start Date :
Oct 15, 2020
Anticipated Primary Completion Date :
Oct 15, 2021
Anticipated Study Completion Date :
Oct 15, 2021

Arms and Interventions

Arm Intervention/Treatment
Placebo Comparator: placebo group

people who given placebo to become agroup of comparison with the other group

Procedure: rigid ureteroscopy
endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
Other Names:
  • endoscopic treatment of ureteric stone
  • Active Comparator: tamsulosin group

    people who given tamsulosin to know the effect on ureteroscopy and compare with the control group

    Procedure: rigid ureteroscopy
    endoscopic treatment of ureteric stones by extraction or peumatic desintegration or laser
    Other Names:
  • endoscopic treatment of ureteric stone
  • Outcome Measures

    Primary Outcome Measures

    1. Rate of patients develop spontaneous expulsion of stone [up to 3 weeks pre operative]

      the stone spontaneously expelled without intervension

    2. Number of patients showing dilated ureteric orifice [intraoperative]

      during ureteroscopy easy introduction in the ureter

    3. Number of patients need dilatation below stone [intraoperative]

      difficult introduce the ureteroscope and reach the stone

    4. Number of patients need dormia extraction or forceps without disintegration [intraoperative]

      that is due to dilated ureter so easy remove the stone

    5. Time of operation from introduction of ureteroscope until stone extraction [intraoperative]

      to know how easy introduction and expulsion of the ureteroscope

    Secondary Outcome Measures

    1. Rate of patients developed side effect from tamsulosin [up to 3 weeks pre operative]

      any side effect from alpha blocker

    2. Rate of patients developed complication [intraoperative]

      any compliction during ureteroscopy such as perforation

    3. Number of patients show failure of ureteroscopy [intraoperative]

      failed introduction or extraction of stone

    4. Number of patients show residual stone post ureteroscopy [postoperative 4 weeks]

      difficulty in expulsion of all stones

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 75 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Lower ureteral stone.

    • Age: 18 - 75 years.

    • normal renal function.

    • single sided ureteral stone with normal other kideny.

    • sign the informed consent.

    • Be willing/able to adhere to follow up visits.

    Exclusion Criteria:
    • Upper and middle ureteral stones.

    • renal impairment.

    • Age < 18 years or 75 < years.

    • female who were pregnant

    • bilateral ureteric stone or solitary kidney.

    • urinary tract infection need drainage.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Mahmoud Ahmed Gaber Asyūţ Assiut Egypt 71511

    Sponsors and Collaborators

    • Assiut University

    Investigators

    • Study Director: ahmed m abdel hamed, Assiut University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Mahmoud Ahmed Gaber, Assistant Lecturer, Assiut University
    ClinicalTrials.gov Identifier:
    NCT04602403
    Other Study ID Numbers:
    • tamsulosin and uretroscopy
    First Posted:
    Oct 26, 2020
    Last Update Posted:
    Oct 26, 2020
    Last Verified:
    Oct 1, 2020
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Oct 26, 2020